36. Epidermolysis bullosa
147 clinical trials,   170 drugs   (DrugBank: 40 drugs),   32 drug target genes,   113 drug target pathways

Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04213261
(ClinicalTrials.gov)
June 9, 20202/12/2019A Study of FCX-007 for Recessive Dystrophic Epidermolysis BullosaA Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaBiological: FCX-007 (debcoemagene autoficel; see below for FCX-007 description)Fibrocell Technologies, Inc.NULLRecruiting2 YearsN/AAll24Phase 3United States